3 stocks that insiders buy

When insiders buy stock, it indicates that they are confident in the company’s prospects or that they view the stock as a bargain. Either way, this indicates a chance to go long on the stock. Insider purchases should not be considered the sole indicator for making an investment or trading decision. At best, it can convince a purchase decision.

Below are some recent notable insider purchases. For more, check out Benzinga’s Insider Trading platform.

Cricut

The trade: Cricut, Inc. (NASDAQ: CRCT) 10% owner Abdiel Capital Management Llc, Abdiel Qualified Master Fund Lp, Abdiel Capital Lp, Abdiel Capital Advisors Lp, Colin Moran acquired a total of 88642 shares at an average price of $28.41. The insider spent $2,518,272.12 to acquire that stock.

What is going on: Barclays downgraded Cricut’s rating from Overweight to Equal-Weight last week.

What Cricut does: Cricut Inc designs and builds a creativity platform that allows users to turn ideas into professional looking handmade products.

Myovant Sciences

The trade: Myovant Sciences Ltd. (NYSE: MYOV) 10% owner Sumitomo Chemical Co Ltd, Dainippon Sumitomo Pharma Co Ltd, Sumitovant Biopharma Ltd acquired a total of 63008 shares at an average price of $22.40. To acquire these shares, it cost $1,411,426.82.

What is going on: Myovant Sciences recently appointed Uneek Mehra as Chief Financial and Business Officer.

What Myovant Sciences does: Myovant Sciences is a healthcare company focused on redefining healthcare for women and men.

Nautilus Biotechnology

The trade: Nautilus Biotechnology, Inc. (NASDAQ: NAUT) Director Matt McIlwaina bought a total of 36970 shares at an average price of $7.71. The insider spent $285,040.80 to acquire those shares.

What is going on: The company reported a larger-than-expected quarterly loss earlier this month.

What Nautilus Biotechnology Does: Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology to quantify and unlock the complexities of the human proteome.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.